Quince Therapeutics completed the sale of Quince SpA, related AIDE intellectual property and equipment to Ayma for $450,000. The transaction matters to investors because it transfers Assets tied to the company’s A-T treatment technology while Quince also assumes a $1,014,489.04 severance payment obligation to Charles Ryan.

Key Highlights

  • Charles Ryan’s employment with Quince Therapeutics ended on September 8, 2026.
  • The separation agreement provides Ryan with a $1,014,489.04 lump-sum cash payment.
  • Quince Therapeutics completed the sale of Quince SpA, related AIDE intellectual property and associated systems to Ayma for $450,000.
  • The transaction includes intellectual property tied to Quince’s eDSP product candidate for Ataxia-Telangiectasia, along with all AIDE and eDSP machines and systems.

Quince Therapeutics, Inc. (NASDAQ: QNCX) completed the sale of Quince SpA, related AIDE intellectual property and associated systems to Ayma for $450,000. The transaction covers assets connected with the company’s encapsulated dexamethasone sodium phosphate product candidate for Ataxia-Telangiectasia.

Ayma Acquires Quince’s AIDE Assets

Ayma acquired all issued and outstanding Equity interests in Quince SpA, along with intellectual property tied to Quince’s proprietary Autologous Intracellular Drug Encapsulation technology. The transferred intellectual property relates to the company’s eDSP product candidate, which uses a patient’s own red blood cells. The deal also includes all AIDE and eDSP machines and systems. Quince Therapeutics completed the transaction on September 8, 2026.

Ryan Departure Carries Severance Obligation

Under the separation agreement, the company will pay Ryan a gross lump sum of $1,014,489.04, subject to his execution and non-revocation of the release obligations. Payment is due after the agreement’s effective date, while Ryan also agreed to release claims, return company property and provide post-separation cooperation.